Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q3 2022 · 10-Q
Revenue$26.51M$26.51M−13.8% vs Q3 2021 Net Income-$75.48M-$75.48MN/M vs Q3 2021 EPS Diluted-$1.75-$1.75N/M vs Q3 2021 Operating Income-$71,045,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$55,506,000N/M Margins · derivedOperating margin-268.0%−81.6 pt vs Q3 2021
Net margin-284.7%−94.9 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 3, 2022 · 34 d after period end